Hyperlipidemias: Clinical Trials

260 trials for Hyperlipidemias, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

260 completed. 260 Phase 2, 30 Phase 3, 24 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 2260Completed 260
Phase 330Completed 30
Phase 124Completed 24

Follow Hyperlipidemias: new trials by email Literature Review of Hyperlipidemias trials Research Report on Hyperlipidemias

Trials (filtered) newest first · largest first

All 260 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Evaluate the Safety, Efficacy of SYH2053 in Chinese Participants With Non-familial Hypercholesterolemia and Mixed Hyperlipidemia
SYH2053/placebo injection, Inclisiran (Leqvio®) 300mg - Hypercholesterolemia and Mixed Hyperlipidemia
Phase 2CompletedCSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.1562024-12-032026-02-19
Effects of RDX-002 on Postprandial Triglycerides in Patients Discontinuing GLP-1 Agonists
RDX-002, Placebo - Triglycerides, Weight Gain Trajectory
Phase 2CompletedResponse Pharmaceuticals682024-09-272026-07-02
A Phase II Study to Evaluate the Efficacy and Safety of of DR10624 in Subjects With Severe Hypertriglyceridemia
DR10624 Injection, Placebo - Severe Hypertriglyceridemia
Phase 2CompletedZhejiang Doer Biologics Co., Ltd.792024-08-012026-01-13
Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemia
SHR-1918; SHR-1918 Placebo - Hyperlipidemia
Phase 2CompletedBeijing Suncadia Pharmaceuticals Co., Ltd442024-07-022026-02-05
Evaluate the Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia
SHR-1918 - Homozygous Familial Hypercholesterolemia
Phase 2CompletedBeijing Suncadia Pharmaceuticals Co., Ltd262023-12-222025-09-05
Study of MAR001 in Adults With Metabolic Dysfunction
MAR001, Placebo - Hypertriglyceridemia
Phase 1 / Phase 2CompletedMarea Therapeutics552023-07-222025-11-13
Study of the Efficacy and Safety of NST-1024 Versus Placebo in Subjects With Hypertriglyceridemia
NST-1024, Placebo - High Triglycerides
Phase 2CompletedNorthSea Therapeutics B.V.502023-06-302025-04-24
A Phase II Study to Evaluate the Safety and Efficacy of SAL003 Combined With Atorvastatin in Hypercholesterolemia and Mixed Dyslipidemia
SAL003 140mg+Atorvastatin, SAL003 420mg+Atorvastatin, Placebo 140mg+Atorvastatin - Hypercholesterolemia and Mixed Dyslipidemia
Phase 2CompletedShenzhen Salubris Pharmaceuticals Co., Ltd.2142023-06-022025-12-12
Study of HSK31679 in Subjects With Hypercholesterolemia With Nonalcoholic Fatty Liver Disease(NAFLD)
HSK31679 low dose, HSK31679 medium dose, HSK31679 high dose - Hypercholesterolemia
Phase 2CompletedHaisco Pharmaceutical Group Co., Ltd.2102023-04-262024-04-09
A Clinical Study in Children With Heterozygous Familial Hypercholesterolemia (HeFH) Aged 6 to 17 Treated Once Daily With Bempedoic Acid Oral Dosing (CLEAR Path 1)
Bempedoic acid - Hypercholesterolemia
Phase 2CompletedEsperion Therapeutics, Inc.312023-01-122026-07-17
A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events
LY3473329, Placebo - Lipoprotein Disorder
Phase 2CompletedEli Lilly and Company2332022-11-242025-03-25
A Study of LY3561774 in Participants With Mixed Dyslipidemia
LY3561774, Placebo - Dyslipidemias, Lipid Metabolism Disorders
Phase 2CompletedEli Lilly and Company2052022-07-202025-03-17
A Dose-Finding Study in Japanese Patients to Evaluate the Effect of Obicetrapib as an Adjunct to Stable Statin Therapy.
Obicetrapib, Placebo - Dyslipidemia, Hypercholesterolemia
Phase 2CompletedNewAmsterdam Pharma1022022-06-272024-10-29
A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia
Olezarsen, Placebo - Hypertriglyceridemia, Atherosclerotic Cardiovascular Disease
Phase 2CompletedIonis Pharmaceuticals, Inc.1542022-05-092026-04-23
A Study of the Efficacy and Safety of Enclitide Chloride (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-008)
Enclitide Chloride, Placebo - Hypercholesterolemia, Familial Hypercholesterolemia
Phase 2CompletedMerck Sharp & Dohme LLC3812022-03-102024-12-09
Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Therapy
Obicetrapib, Ezetimibe 10mg, Obicetrapib placebo - Dyslipidemias, High Cholesterol
Phase 2CompletedNewAmsterdam Pharma1192022-03-092024-07-03
Supplementation of Oil Palm Phenolics to Improve Lipid Profile in Subjects With Minor Hyperlipidaemia
Placebo, 250 mg OPP - Hyperlipidemias, Hypercholesterolemia
Phase 2CompletedIsa Naina Mohamed502021-10-182022-04-13
A Study to Assess the Safety, Efficacy and Tolerability of AZD8233 Treatment in Participants With Hyperlipidaemia
AZD8233, Placebo - Hyperlipidaemia
Phase 2CompletedAstraZeneca4112021-07-072023-12-15
Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia
ARO-APOC3, Placebo - Severe Hypertriglyceridemia
Phase 2CompletedArrowhead Pharmaceuticals2292021-05-312026-03-24
Supplements, Placebo, or Rosuvastatin Study
Fish Oil, Cinnamon, Garlique,Turmeric, Plant Sterol, Red Yeast Rice, Rosuvastatin, Placebo - Hypercholesterolemia
Phase 2CompletedThe Cleveland Clinic2032021-04-232023-05-25

Showing 20 of 260. Sign in to see all of them.

Narrower conditions

Hypercholesterolemia (122)  ·  Hypertriglyceridemia (58)  ·  Dyslipidemias (39)  ·  Cardiovascular Diseases (22)  ·  Hyperlipoproteinemia Type II (22)  ·  Hypertension (15)  ·  Metabolic Syndrome (15)  ·  Diabetes Mellitus (14)  ·  Atherosclerosis (12)  ·  Homozygous Familial Hypercholesterolemia (12)  ·  Lipid Metabolism Disorders (12)  ·  Obesity (12)  ·  Insulin Resistance (11)  ·  Metabolic Diseases (11)

Broader conditions

Nutritional and Metabolic Diseases (259)  ·  Metabolic Diseases (249)  ·  Lipid Metabolism Disorders (248)  ·  Dyslipidemias (221)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (37)  ·  Genetic Diseases, Inborn (34)  ·  Lipid Metabolism, Inborn Errors (33)  ·  Glucose Metabolism Disorders (32)  ·  Metabolism, Inborn Errors (32)  ·  Hyperlipoproteinemias (31)  ·  Vascular Diseases (30)  ·  Pathological Conditions, Signs and Symptoms (27)  ·  Cardiovascular Diseases (24)  ·  Endocrine System Diseases (21)

Interventions

Atorvastatin (29)  ·  Ezetimibe (16)  ·  Fenofibrate (11)  ·  8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid (10)  ·  evolocumab (10)  ·  Hydroxymethylglutaryl-CoA Reductase Inhibitors (8)  ·  Rosuvastatin Calcium (8)  ·  alirocumab (8)  ·  gemcabene (7)  ·  mipomersen (7)  ·  BMS201038 (5)  ·  Fish Oils (5)  ·  Pravastatin (5)  ·  ALN-PCS (4)  ·  Exercise (4)

Sponsors

Esperion Therapeutics, Inc. (10)  ·  Amgen (9)  ·  Kastle Therapeutics, LLC (7)  ·  University of Toronto (7)  ·  AstraZeneca (6)  ·  Merck Sharp & Dohme LLC (6)  ·  NeuroBo Pharmaceuticals Inc. (6)  ·  Regeneron Pharmaceuticals (6)  ·  Aegerion Pharmaceuticals, Inc. (5)  ·  Eli Lilly and Company (5)  ·  National Heart, Lung, and Blood Institute (NHLBI) (5)  ·  Novartis Pharmaceuticals (5)  ·  Pfizer (5)  ·  Sanofi (5)  ·  University Health Network, Toronto (5)

Countries

United States (131)  ·  Canada (72)  ·  Netherlands (30)  ·  China (17)  ·  Germany (15)  ·  Japan (15)  ·  Australia (14)  ·  Denmark (14)  ·  Hungary (12)  ·  Czechia (11)  ·  Italy (11)  ·  France (10)  ·  Poland (10)  ·  Spain (10)  ·  United Kingdom (10)

Top investigators

Jean-Claude Tardif, MD (4)  ·  David JA Jenkins, MD, PhD, DSc (3)  ·  David Crowley, MD (2)  ·  Eli Roth, MD (2)  ·  Gary F Lewis, MD (2)

Results publications

PMID 30183102, PMID 37994400, PMID 22301925, PMID 26872608, PMID 34677608, PMID 20707601, PMID 21518985, PMID 24014831, PMID 25060413, PMID 25091629, PMID 25660356, PMID 28181260, PMID 28324110, PMID 29037448, PMID 31194872, PMID 33990512, PMID 34223895, PMID 38018702, PMID 38415744, PMID 11914243, PMID 12221048, PMID 12805393, PMID 16996859, PMID 17030154, PMID 17215532, PMID 17298834, PMID 17325296, PMID 17384435, PMID 17392721, PMID 17434849, PMID 17556685, PMID 17563345, PMID 17971707, PMID 17987126, PMID 18018771, PMID 19364997, PMID 19500003, PMID 19506174, PMID 19592624, PMID 19727665, PMID 19810001, PMID 19843338, PMID 20008831, PMID 20220185, PMID 20378080, PMID 20428452, PMID 20435205, PMID 20527967, PMID 20660224, PMID 20668250

NIH funding

2016 (4), 2005 (2), 2015 (1), 2017 (1), 2019 (1), M01RR000096 (1), M01RR000334 (1), R01DK058785 (1), R01DK088114 (1), R01HL042554 (1), R01HL057354 (1), R01HL070742 (1), R21AG023805 (1), U01HL044315 (1)